Latest Breaking News On - Caisson biotech - Page 1 : comparemela.com

AUSTIN, Texas /Massachusetts Newswire – National News/ Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings. The HEPtune platform, which utilizes heparosan, a naturally occurring polysaccharide, has been validated as a novel half-life extension and drug delivery alternative to commonly used polyethylene glycol (PEG). Unlike PEG, heparosan is naturally found in humans, is completely biodegradable, and will not trigger anaphylactic shock or anti-drug antibodies. The HEPtune platform has been applied to numerous drug classes including biologics, and small molecules via nanocarriers, including liposomes.

United statesPaul deangelisEmergent technologies incCaisson biotechEuropean patent officeUniversity of oklahoma health sciences centerNational newsStanford universityUniversity of oklahoma professor drMassachusetts newswirePresidential professorOklahoma health sciences centerChief scientistOklahoma professorEmergent technologiesஒன்றுபட்டது மாநிலங்களில்